Enhancing Rose Bengal penetration in ex vivo human corneas using iontophoresis.

IF 3 Q2 PHARMACOLOGY & PHARMACY Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-18 DOI:10.1080/20415990.2024.2371778

James M Lai, Justin Chen, Juan Carlos Navia, Heather Durkee, Alex Gonzalez, Cornelis Rowaan, Timothy Arcari, Mariela C Aguilar, Katrina Llanes, Noel Ziebarth, Jaime D Martinez, Darlene Miller, Harry W Flynn, Guillermo Amescua, Jean-Marie Parel

{"title":"Enhancing Rose Bengal penetration in ex vivo human corneas using iontophoresis.","authors":"James M Lai, Justin Chen, Juan Carlos Navia, Heather Durkee, Alex Gonzalez, Cornelis Rowaan, Timothy Arcari, Mariela C Aguilar, Katrina Llanes, Noel Ziebarth, Jaime D Martinez, Darlene Miller, Harry W Flynn, Guillermo Amescua, Jean-Marie Parel","doi":"10.1080/20415990.2024.2371778","DOIUrl":null,"url":null,"abstract":"Aim: Rose Bengal photodynamic antimicrobial therapy (RB-PDAT) has poor corneal penetration, limiting its efficacy against acanthamoeba keratitis (AK). Iontophoresis enhances corneal permeation of charged molecules, piquing interest in its effects on RB in ex vivo human corneas.Methods: Five donor whole globes each underwent iontophoresis with RB, soaking in RB, or were soaked in normal saline (controls). RB penetration and corneal thickness was assessed using confocal microscopy.Results: Iontophoresis increased RB penetration compared with soaking (177 ± 9.5 μm vs. 100 ± 5.7 μm, p < 0.001), with no significant differences in corneal thickness between groups (460 ± 87 μm vs. 407 ± 69 μm, p = 0.432).Conclusion: Iontophoresis significantly improves RB penetration and its use in PDAT could offer a novel therapy for acanthamoeba keratitis. Further studies are needed to validate clinical efficacy.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"567-575"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412146/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2024.2371778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Rose Bengal photodynamic antimicrobial therapy (RB-PDAT) has poor corneal penetration, limiting its efficacy against acanthamoeba keratitis (AK). Iontophoresis enhances corneal permeation of charged molecules, piquing interest in its effects on RB in ex vivo human corneas.Methods: Five donor whole globes each underwent iontophoresis with RB, soaking in RB, or were soaked in normal saline (controls). RB penetration and corneal thickness was assessed using confocal microscopy.Results: Iontophoresis increased RB penetration compared with soaking (177 ± 9.5 μm vs. 100 ± 5.7 μm, p < 0.001), with no significant differences in corneal thickness between groups (460 ± 87 μm vs. 407 ± 69 μm, p = 0.432).Conclusion: Iontophoresis significantly improves RB penetration and its use in PDAT could offer a novel therapy for acanthamoeba keratitis. Further studies are needed to validate clinical efficacy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用离子透入技术提高罗斯孟加拉红在体外人类角膜中的渗透率。

目的：玫瑰红光动力抗菌疗法（RB-PDAT）的角膜渗透性较差，限制了其对阿卡巴氏角膜炎（AK）的疗效。电离子透入疗法可增强带电分子在角膜上的渗透性，这引起了人们对电离子透入疗法在体外人类角膜上对 RB 的影响的兴趣。方法：五个供体全球分别接受 RB 离子透入、RB 浸泡或正常生理盐水浸泡（对照组）。使用共聚焦显微镜评估 RB 的渗透性和角膜厚度。结果与浸泡相比，离子透入法增加了 RB 穿透力（177 ± 9.5 μm vs. 100 ± 5.7 μm，P = 0.432）。结论离子透入疗法能明显提高 RB 的穿透力，在 PDAT 中使用这种疗法可为棘阿米巴角膜炎提供一种新的疗法。临床疗效还需进一步研究验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.